Medicare backs away from some anemia drug restrictions

Medicare has backed away from some of the restrictions it previously proposed for anemia drugs made by Johnson & Johnson and Amgen, which were considered overprescribed. Patient advocacy groups had complained about the restrictions proposed two months ago for J&J's Procrit and Amgen's Epogen and Aranesp. The program won't cover the use of the drugs to treat anemia caused by cancer, only anemia that's related to chemotherapy.

View Full Article in: · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC